Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma

Nature Reviews Urology, Published online: 21 November 2022; doi:10.1038/s41585-022-00676-0The approval of immunotherapy agents to treat patients with metastatic renal cell carcinoma revolutionized the therapeutic landscape for this disease, but a large number of patients still do not experience objective and durable response, and biomarkers to identify response to immunotherapy are urgently needed. In this Review, the authors describe strength and limitations of currently available prognostic and predictive biomarkers in metastatic renal cell carcinoma and discuss emerging promising biomarkers that deserve further investigation.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research